文献速递关节外科

关节腔内碳青霉烯输注一期翻修有效治疗革兰阴性菌所致慢性假体周围关节感染

One-stage revision using intra-articular carbapenem infusion effectively treats chronic periprosthetic joint infection caused by Gram-negative organisms.
PubMed 文献 · Bone Joint J · 2023-03-01

该回顾性研究纳入2013年11月至2020年3月间接受一期翻修联合关节腔内碳青霉烯输注的32例革兰阴性菌假体周围关节感染患者(22髋、11膝),平均随访55.1个月,仅3例(9.4%)治疗失败,末次随访Harris髋关节评分平均81分、HSS膝关节评分平均79分,作者认为该方案可有效控制感染且并发症少,但提示一代、二代头孢菌素及青霉素耐药率高应慎用。

要点

  • 32例革兰阴性菌假体周围关节感染行一期翻修联合关节腔内碳青霉烯输注,仅3例(9.4%)治疗失败。
  • 革兰阴性菌以大肠埃希菌(8/34)、阴沟肠杆菌(7/34)、肺炎克雷伯菌(5/34)为主,7例(7/32)为混合感染。
  • 青霉素、头孢菌素、喹诺酮类及磺胺类耐药率均>10%,青霉素及部分头孢菌素(一代、二代)耐药率>30%。

核心结论

  • 关节腔内碳青霉烯输注联合一期翻修可有效控制革兰阴性菌感染,获得可接受的临床结果且并发症少。
  • 作者指出,由于耐药率高,一代、二代头孢菌素及青霉素应慎用。

研究设计与样本

  • 回顾性研究,纳入2013年11月至2020年3月间接受一期翻修联合关节腔内碳青霉烯输注的32例患者(22髋、11膝)。
  • 单种革兰阴性菌感染予关节腔内及静脉碳青霉烯输注;包括革兰阴性菌的混合感染予静脉万古霉素联合关节腔内碳青霉烯及万古霉素。
  • 以再感染或PJI所致死亡为治疗失败,评估细菌分布、药敏、感染控制率、功能恢复及并发症。

主要发现

  • 革兰阴性菌PJI主要致病菌为大肠埃希菌(8/34)、阴沟肠杆菌(7/34)、肺炎克雷伯菌(5/34),7例(7/32)为混合感染。
  • 32例中仅3例(9.4%)治疗失败,平均随访55.1个月(SD 25至90)。
  • 末次随访Harris髋关节评分平均81分(62至91),HSS膝关节评分平均79分(56至89)。
  • 1例发生瘘管,另1例感染关节局部出现皮疹。

关键数值与推荐

  • 青霉素、头孢菌素、喹诺酮类及磺胺类耐药率均>10%,青霉素及部分头孢菌素(一代、二代)耐药率>30%。
  • 功能评分:Harris髋关节评分平均81分(62至91),HSS膝关节评分平均79分(56至89)。

临床怎么用

  • 关节腔内碳青霉烯输注联合一期翻修可用于治疗革兰阴性菌假体周围关节感染。
  • 作者建议,因耐药率高,一代、二代头孢菌素及青霉素应慎用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gram-negative periprosthetic joint infection (PJI) has been poorly studied despite its rapidly increasing incidence. Treatment with one-stage revision using intra-articular (IA) infusion of antibiotics may offer a reasonable alternative with a distinct advantage of providing a means of delivering the drug in high concentrations. Carbapenems are regarded as the last line of defense against severe Gram-negative or polymicrobial infection. This study presents the results of one-stage revision using intra-articular carbapenem infusion for treating Gram-negative PJI, and analyzes the characteristics of bacteria distribution and drug sensitivity. We retrospectively reviewed 32 patients (22 hips and 11 knees) who underwent single-stage revision combined with IA carbapenem infusion between November 2013 and March 2020. The IA and intravenous (IV) carbapenem infusions were administered for a single Gram-negative infection, and IV vancomycin combined with IA carbapenems and vancomycin was applied for polymicrobial infection including Gram-negative bacteria. The bacterial community distribution, drug sensitivity, infection control rate, functional recovery, and complications were evaluated. Reinfection or death caused by PJI was regarded as a treatment failure. Gram-negative PJI was mainly caused by Escherichia coli (8/34), Enterobacter cloacae (7/34), and Klebsiella pneumoniae (5/34). Seven cases (7/32) involved polymicrobial PJIs. The resistance rates of penicillin, cephalosporin, quinolones, and sulfonamides were > 10%, and all penicillin and partial cephalosporins (first and second generation) were > 30%. Of 32 cases, treatment failed to eradicate infection in only three cases (9.4%), at a mean follow-up of 55.1 months (SD 25 to 90). The mean postoperative Harris Hip Score and Hospital for Special Surgery knee score at the most recent follow-up were 81 (62 to 91) and 79 (56 to 89), respectively. One patient developed a fistula, and another presented with a local rash on an infected joint. The use of IA carbapenem delivered alongside one-stage revision effectively controlled Gram-negative infection and obtained acceptable clinical outcomes with few complications. Notably, first- and second-generation cephalosporins and penicillin should be administrated with caution, due to a high incidence of resistance.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Li Y, Zhang X, Ji B, et al. One-stage revision using intra-articular carbapenem infusion effectively treats chronic periprosthetic joint infection caused by Gram-negative organisms. Bone Joint J. 2023. PMID: 36854321. doi:10.1302/0301-620X.105B3.BJJ-2022-0926.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。